You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Wearable Fluorescence Imaging Device for Intraoperative Identification of Brain Tumors

    SBC: BIOPTICS TECHNOLOGY LLC            Topic: 102

    ABSTRACTApproximatelypeople in the United States have been diagnosed with a primary brain tumorOf thesemalignant gliomasMGsaccount for approximatelyof all intracranial tumorswith an overall patient survival rate of onlyMore than any other cancerbrain cancer has lasting physicalcognitiveand psychological impacts on a patient s lifeand the highest per patient initial cost of careSurgical resection r ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen

    SBC: Arrevus, Inc.            Topic: NIAID

    Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Peptidomic Rapid Point-of-Care TB Diagnostic

    SBC: NEW YORK UNIVERSITY            Topic: NIAID

    DESCRIPTION (provided by applicant): The goals of this proposal are to devise rapid serological tests that can replace the sputum smear test for the diagnosis of active TB and meets the WHO specifications to replace microscopy in resource-limited countries based on immunodominant peptides from three M. tb cell-wall proteins. Although direct smear microscopy is highly specific, the test is tedious, ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers

    SBC: NAJIT TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking of complementary RNA PPMO are composed of two components an antisense morpholino oligomer cargo covalently conjugated to a cell penetrating delivery peptide PPMO are completely nuclease resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a novel Balloon Occlusion Sheath for Stroke (BOSS)

    SBC: Marblehead Medical LLC            Topic: 106

    PROJECT SUMMARY ABSTRACTThis research program s broadlong term objective is to improve health outcomes for patients suffering fromacute ischemic strokeAISresulting from large vessel occlusionsWe will achieve this purpose by developingimproved access tools for stroke intervention procedureswhich specifically target tool innovations that providesupport for embolectomy devices and arrest flow during ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a new approach to screening for language impairments

    SBC: ELLENSON INTEGRATION ENTERPRISES, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): This Small Business Technology and Transfer (STTR) Fast Track proposal focuses on the translation of innovative research protocols for diagnosing Specific Language Impairment (SLI) into an innovative, easy-to- use app-based screener with high potential for private sector commercialization. SLI is a form of language impairment with no known cause, with a strong ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Alkontrol herbal for Treating Alcohol Abuse

    SBC: NATURAL PHARMACIA INTERNATIONAL, INC.            Topic: NIAAA

    DESCRIPTION provided by applicant This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia International Inc NPI and McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholism Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal a ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Project SummaryOver $billion is spent annually in the US treating chronicnon healing woundsmany of which face lifethreatening complications due to infectionsWound infections are difficult to treat due to the frequency of antibiotic resistance as well as the formation of biofilmsa community of bacteria covered by an extracellular polymeric substanceBiofilm related infections can result in a substan ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Urinary tract infectionsUTIsare one of the most common hospital acquired infections and are often caused by multi drug resistantMDRbacterial pathogensMDR bacterial pathogens are associated with significant morbidity and mortalitycreating enormous healthcare and economic burdens due to variations in disease natural histories as well as the lack of effective therapeutic optionsTreatment option limit ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government